Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) EBIT Margin (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed EBIT Margin for 9 consecutive years, with 11.54% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin rose 216.0% year-over-year to 11.54%, compared with a TTM value of 17.35% through Sep 2025, down 229.0%, and an annual FY2024 reading of 16.67%, up 320.0% over the prior year.
  • EBIT Margin was 11.54% for Q3 2025 at Sunshine Biopharma, up from 21.83% in the prior quarter.
  • Across five years, EBIT Margin topped out at 11.54% in Q3 2025 and bottomed at 3184.5% in Q1 2021.
  • Average EBIT Margin over 5 years is 462.03%, with a median of 21.83% recorded in 2025.
  • The sharpest move saw EBIT Margin plummeted -284493bps in 2021, then surged 218701bps in 2022.
  • Year by year, EBIT Margin stood at 328.52% in 2021, then tumbled by -81bps to 593.01% in 2022, then soared by 97bps to 15.46% in 2023, then crashed by -37bps to 21.24% in 2024, then skyrocketed by 46bps to 11.54% in 2025.
  • Business Quant data shows EBIT Margin for SBFM at 11.54% in Q3 2025, 21.83% in Q2 2025, and 14.56% in Q1 2025.